Talk:Sinopharm BIBP COVID-19 vaccine

Requested move 12 August 2021

 * The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion. 

The result of the move request was: Moved to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine. per discussion consensus and consistency policies. (non-admin closure) — Shibboleth ink  (♔ ♕) 15:22, 26 August 2021 (UTC)

– Following WP:MEDTITLE and WP:MEDORG, the World Health Organization seems to prefer Sinopharm BIBP and Sinopharm WIBP over BBIBP/BBIBP-CorV and WIBP-CorV. English-speaking media mostly uses Sinopharm vaccine, ignoring the existence of WIBP-CorV. If this request is approved, then naturally WIBP-CorV would be moved to Sinopharm COVID-19 vaccine WIBP for consistency. Fernando Trebien (talk) 20:27, 12 August 2021 (UTC) — Relisting. D🐶ggy54321 (let's chat!) 21:16, 19 August 2021 (UTC) The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.
 * BBIBP-CorV → Sinopharm COVID-19 vaccine BIBP
 * WIBP-CorV → Sinopharm COVID-19 vaccine WIBP
 * Comment. I think Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine would be more more consistent with how other vaccines are named within Wikipedia. No need to split up the two parts of each name.  John P. Sadowski (NIOSH) (talk) 03:30, 14 August 2021 (UTC)
 * Weak move to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine. I have no problems with the current title, but if I have to choose, 's suggestion the best way to go. — hueman1 ( talk •  contributions ) 13:23, 14 August 2021 (UTC)
 * Comment. Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine seem ok to me. --Fernando Trebien (talk) 15:30, 14 August 2021 (UTC)
 * Support per John P. Sadowski (NIOSH). Abrilando232 (talk) 23:00, 14 August 2021 (UTC)
 * Relisting comment: there seems to be a consensus that Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine are both good alternative titles, and I am relisting so the discussion can be more focused on which of the two potential suggestions I just listed would be a better title for the page. Thanks! D🐶ggy54321 (let's chat!) 21:16, 19 August 2021 (UTC)
 * support per John P. Sadowski--Ozzie10aaaa (talk) 01:23, 22 August 2021 (UTC)
 * Note: WikiProject COVID-19 has been notified of this discussion. —  Shibboleth ink  (♔ ♕) 02:04, 20 August 2021 (UTC)
 * Note: WikiProject China has been notified of this discussion. —  Shibboleth ink  (♔ ♕) 02:05, 20 August 2021 (UTC)
 * Note: WikiProject Medicine has also been notified of this discussion. 2409:4061:700:93AF:418E:4466:2FDB:DC48 (talk) 19:20, 21 August 2021 (UTC)
 * I support moving the pages to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine. WhatamIdoing (talk) 18:23, 22 August 2021 (UTC)

Semi-protected edit request on 10 September 2021
change "emergency used authorization" to "emergency use authorization" 2001:EE0:1A1:5484:7280:4C94:88BE:3F67 (talk) 18:14, 10 September 2021 (UTC)
 * ✅ Extraordinary Writ (talk) 04:59, 11 September 2021 (UTC)

Wrong information
Authorizations . . . On 5 May 2021, EMA's human medicines committee (CHMP) has started a rolling review of the vaccine. The EU applicant for this medicine is the Italian company Life'On S.r.l.[84]

There is no ongoing EMA Rolling Review for Sinopharm BIBP-CorV. The information stated in literature reference 84 relates to the vaccine CoronaVac from SinoVac. --Benedikt.ebli (talk) 19:38, 2 February 2022 (UTC)

Antibody Response to Sinopharm COVID-19 Vaccine in Cancer Patients:
[In 2021, a cross-sectional study was conducted on 74 patients with various types of cancers in Iran. These patients had received two doses of the Sinopharm vaccine. The study measured levels of SARS-CoV-2 neutralizing antibodies, Anti-RBD, and Anti-Spike IgG for 4 to 6 weeks after the second vaccine dose. Positive neutralizing antibody status was observed in 41 individuals (55.4%). Additionally, 31 people (41.9%) tested positive for antibodies against RDB antigen, and 20 people (27%) had antibodies against Spike virus antigen. ref: https://jmums.mazums.ac.ir/article-1-20689-en.html] Reza nava (talk) 16:40, 2 May 2024 (UTC)